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Many seminal discoveries in molecu-
lar biology have their origin in seeking 
differences between one functional 
state of a biological system versus 
another. Ubiquitination, for example, 
was first discovered by comparing 
stressed cells with cells under normal 
conditions. Knowledge of growth fac-
tor signaling owes much to comparing 
cells transformed with Rous sarcoma 
virus with their normal counterparts. 
Such discoveries have necessarily 
involved a great deal of luck as they 
relied on finding the critical difference 
in the part of the system that we are 
able to measure, hence the attraction 
of comprehensive or system-wide 
analyses.
Differences between cellular states 
are reflected in changes in gene 
expression that manifest themselves 
at the level of both the message 
(mRNA) and the final product (protein). 
The first “genome-wide” method for 
expression analysis was the large-
scale hybridization of mRNA to com-
plementary sequences immobilized on 
chips. As each possible message can 
be placed on the chip at a known loca-
tion, microarrays can in principle cover 
the whole transcriptome. Despite their 
ubiquity and tremendous usefulness, 
microarrays have certain limitations. 
These are partly technology related; 
for example, issues with reproducibil-
ity across platforms and laboratories 
have not been fully resolved (Canales 
et al., 2006). More important is the 
nonquantitative nature of the micro-
array measurements in predicting the 
amount of change in the active mature 
protein. Proteins are almost always the 
effectors of biological functions, but 
protein levels depend not only on the 
levels of the corresponding messages 
but also on a host of translational con-
trols and regulated degradation (Gygi 
et al., 1999b; Lu et al., 2007). These 
factors may be just as important as 
increased synthesis of mRNA and 
they cannot be measured directly by 
microarrays.
The expression levels of all proteins 
would arguably provide the most rel-
evant single data set characterizing 
a biological system. Thus the idea of 
“proteomics,” which aims to provide 
just that, has had strong appeal even 
before the term was coined a decade 
ago. From the mid 1970s, proteomics 
was pursued with two-dimensional 
gel electrophoresis, but unfortunately 
that technology never fully deliv-
ered on its promise. Biological mass 
spectrometry (MS), the technologi-
cal basis of most current proteomics 
studies, was first catapulted to main-
stream prominence with the develop-
ment of the electrospray and MALDI 
ionization techniques. This advance 
made biological molecules read-
ily amenable to mass spectrometry 
and garnered the Chemistry Nobel 
Prize in 2002. A number of decisive 
breakthroughs followed, including 
protocols to handle small amounts 
of biological samples, the ability to 
rapidly identify peptides by match-
ing their MS fragmentation spectra to 
sequence databases, and the direct 
analysis of very complex protein mix-
tures (Aebersold and Mann, 2003; 
Yates et al., 2005). Most recently, 
high performance but robust MS 
instruments have further increased 
the power of MS-based proteomics 
at a furious clip. Mass spectrometry 
has also become a powerful tool for 
detecting posttranslational modifica-
tions and protein interactions.
Meanwhile, progress on quantita-
tive methods has been slower. As MS 
is not inherently quantitative, sam-
ples are labeled with stable isotopes. 
Labeling can be performed chemi-
cally by reacting the sample with light 
or heavy versions of an isotope tag, as 
in the original ICAT (Gygi et al., 1999a) 
or the popular iTRAQ methods (Ross 
et al., 2004). Alternatively, whole pro-
teomes can be labeled metabolically 
(Oda et al., 1999; Ong et al., 2002), or 
isotopically labeled peptides can be 
spiked into the proteome to enable 
quantitation of specifically targeted 
peptides (Aebersold, 2003; Gerber 
et al., 2003). Despite these and other 
ingenious approaches (reviewed in 
Ong and Mann, 2005), only limited 
proteomes have been quantified so 
far. Recently, a number of techno-
logical and methodological devel-
opments have combined to change 
this picture, and here we argue that 
MS-based proteomics is finally ready 
for systems-wide measurement 
of protein expression levels. If so, 
many of the powerful systems-wide 
approaches previously restricted to 
the mRNA level could now be per-
formed directly at the protein level. 
Thus, we argue that proteomics could 
become the “new genomics.”
Challenges of Proteome-wide 
Expression Analysis
Despite remarkable progress using 
MS to investigate biological prob-
lems, the challenges of proteomics 
are daunting. Unlike oligonucleotides, 
proteins cannot be amplified and 
therefore sensitivity is of the essence. 
In order to make proteins amenable 
to MS analysis, they first need to be 
digested to peptides. However, this 
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process is not completely uni-
form and also generates many 
redundant versions of abundant 
peptides that are picked up by the 
mass spectrometer. Digestion of 
the roughly 10,000 different gene 
products thought to be present 
in a mammalian cell results in a 
very large number of proteolytic 
peptides, many more than can 
be sequenced by MS during the 
analysis run. Furthermore, not all 
peptides that are fragmented by 
MS are confidently identified by 
search engines. Analyzing these 
factors, Küster et al. estimate that 
less than 10% of peptides pre-
sented to the mass spectrometer 
in adequate amounts actually 
contribute useful peptide identi-
fication (Kuster et al., 2005). As 
a result of these and other limi-
tations, some authorities have 
questioned the capability of MS-
based “shotgun” proteomics to 
ever arrive at a comprehensive 
coverage of any proteome using 
currently established method-
ology (Domon and Aebersold, 
2006; Nielsen et al., 2006). Add-
ing to the challenge, it is not only 
identification of proteins that is 
needed but also comprehensive 
quantitation of protein levels in 
cells.
Quantifying the Proteome
To address the quantitation 
problem, we have used a stable 
isotope-based technique termed 
stable isotope labeling by amino 
acids in cell culture or SILAC 
(Ong et al., 2002). Using the SILAC 
method, cells are metabolically 
labeled by either normal (“light”) 
or “heavy” isotope versions of an 
essential stable (i.e., nonradioactive) 
amino acid, thus enabling the pro-
teomes to be distinguished by MS. 
Each instance of the amino acid is 
labeled in the two proteomes and 
therefore each peptide appears in 
two forms separated on the mass-
to-charge scale by the difference 
between light and heavy label, for 
instance six 13C carbon atoms ver-
sus six 12C carbon atoms. The ratio in 
peak heights between the two forms 
corresponds directly to the differ-
ence in protein amount between the 
two cell states.
Using SILAC technology, we ana-
lyzed the factors preventing complete 
proteome quantitation in yeast, which 
is the only organism to have a reason-
ably well-defined proteome (Ghaem-
maghami et al., 2003). Interestingly, 
we found that raw mass spectromet-
ric sensitivity was already adequate 
for full proteome analysis using mod-
ern instrumentation (de Godoy et al., 
2006). However, there are two other 
parameters limiting the analysis and 
preventing full proteome identifica-
tion. First, the instrument has a 
finite peptide sequencing speed 
and only managed to target one 
third of eluting peptides for frag-
mentation. This problem could 
be readily addressed using more 
intelligent acquisition software to 
avoid repeatedly re-measuring 
the same or closely related pep-
tides. The other limitation is the 
dynamic range of measurement, 
that is, the lowest abundant pep-
tides that can be measured by the 
mass spectrometer in the pres-
ence of the highest abundance pep-
tides. We estimated that sufficient 
dynamic range could be achieved by 
sample fractionation in combination 
with changes in MS instrumentation.
Figure 1 shows an example of using 
the SILAC technology on a mamma-
lian cellular proteome. HeLa cells 
were labeled with two different amino 
acid forms (light and heavy) to directly 
compare two cellular states (Figure 
1A). We detected a total of 239,848 
SILAC peptide doublets and identi-
fied 24,230 nonredundant peptide 
sequences corresponding to 4,034 
quantifiable proteins in the HeLa cell 
Figure 1. SILAC-Based Whole-Pro-
teome Measurements
(A) Two SILAC-encoded cell populations 
are mixed, digested by trypsin, and ana-
lyzed by liquid chromatography-mass 
spectrometry (MS) on a high-resolution 
instrument (LTQ-Orbitrap). 
(B) Expanded view of the MS data from 
one of the analyzed fractions. The signal 
of eluting peptides is plotted and color 
coded as a function of mass and chro-
matographic retention time. Recognized 
SILAC doublets are given the same color. 
Peptides are identified by mass spectro-
metric fragmentation in the ion trap part 
of the instrument. 
(C) Three-dimensional detail of one of 
6600 SILAC peptide doublets quantified 
in this measurement. The cardboard-like 
appearance is due to very high mass res-
olution. Comparison of the two isotope 
clusters reveals that the peptide abun-
dance ratios are 0.85:1 between heavy- 
and light-labeled states. 
(D) Plot of normalized SILAC ratios as a 
function of protein signal. Protein fold-
change is determined from robust aver-
ages of the ratios of the peptides identi-
fying each protein. SILAC ratios for 4033 
proteins were determined from the data 
in (A). Ratios significantly above 1:1 are 
colored in red (upregulation).
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proteome (see Supplemental Data 
available with this article online). This 
demonstrates that modern proteomic 
methods can now quantify a substan-
tial part of a cellular proteome.
Another interesting aspect of the 
experiment is illustrated in Figure 
1D where the protein ratios are plot-
ted as a function of abundance and 
fold change between the light and 
heavy SILAC states. The vast major-
ity of protein ratios are below two, 
which represents excellent quantita-
tive accuracy of gene expression in a 
large-scale experiment.
Proteomics and Transcriptomics 
Are Equally Comprehensive
To compare the current state of 
coverage of MS-based proteomics 
to that obtained with microarray 
expression analysis, we analyzed a 
published data set using Affymetrix 
microarray measurement of gene 
expression in HeLa cells (Carson 
et al., 2004). A comparison of this 
microarray data set with the pro-
teomic HeLa data set mentioned 
above is shown in Figure 2A. A 
large overlap between MS data and 
Affymetrix data is evident, but a sub-
stantial number were only detected 
as either message or protein. Part 
of the latter population is owing to 
the fact that 668 genes correspond-
ing to proteins identified in the Inter-
national Protein Index (IPI) database 
were not represented on the chip. 
Of the total 7,278 genes unambigu-
ously detected either as message 
or protein, MS-based proteomics 
quantified 55% and the microarray 
77%. This shows that both methods 
provide reasonably comprehensive 
“system-wide” measures of gene 
expression.
Depending on the source of cells, 
proteomics rather than microarray 
analysis may be a better investiga-
tional tool. For example, certain tis-
sues and body fluids such as blood 
do not contain representative mRNA 
populations and are better suited 
to proteomics analysis. Figure 2B 
illustrates the feasibility of quanti-
fying such tissues by “label-free” 
proteomics. Label-free proteomics 
refers to the absence of an isotopic 
label and to the fact that quantita-
tion is performed by directly com-
paring MS measurements of the 
different samples. Unlike stable 
isotope-based technologies, label-
free proteomics does not control 
for variations in the sample work 
up and the samples are analyzed 
separately. Therefore, the result-
ing quantitation is generally less 
accurate. In this example, proteins 
in brain tissue samples from two 
individuals were extracted and ana-
lyzed separately by MS. Peptides 
were quantified against each other 
by comparing their total mass spec-
trometric response over the elu-
tion peak. The panel summarizes 
quantitation of several thousand 
proteins. The ratio of most proteins 
is almost 1:1, with relatively good 
quantitation achieved for the higher 
intensity signals. While not as accu-
rate as SILAC-based quantitation, 
performance is roughly similar to 
the quantitative accuracy achieved 
at the message level in standard 
microarray experiments.
Perspectives
Although there are many remain-
ing technological challenges for 
proteomics, the state of the tech-
nology now allows reasonably 
comprehensive quantitation of cel-
lular proteomes. When stable iso-
topes are used, quantitation can be 
very accurate in these large-scale 
experiments, a significant develop-
ment given that this has been the 
aspiration of proteomics for several 
decades. To be sure, proteomics 
still lags years behind microarray 
technology in several aspects. For 
example, microarray measurements 
are currently faster and, because of 
amplification, require less starting 
material than proteomics analyses. 
Furthermore, microarray facilities 
are more accessible than high-end 
proteomics laboratories. However, 
very advanced MS instrumentation 
will soon be available in hundreds 
of laboratories and measurement 
times for comprehensive proteome 
analysis will shrink dramatically in 
the near future.
It is instructive to recall how 
rapidly MS-based proteomics has 
developed over the past decade. 
Ten years ago, the sequencing of a 
single protein at very high sensitiv-
ity was a major undertaking. Today, 
the identification of hundreds of 
proteins in a single experiment is 
almost taken for granted. We proj-
Figure 2. Quantitative Proteomics versus Transcriptomics
(A) Overlap between the proteins identified in the example given in Figure 1 (blue) and the mes-
sages with “present call” (that is, significantly different from zero signal) in a quadruple microarray 
experiment of the normal HeLa cell proteome (green). 
(B) “Label-free” quantitation of about 4000 proteins identified in brain tissue samples from two 
separate individuals. Mass spectrometric intensity counts (added peptide signals) from the two 
separate runs are plotted against each other.
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ect that technological capabilities 
in this field will continue to at least 
double every year for the foresee-
able future: a Moore’s law for pro-
teomics. Furthermore, as pointed 
out by others, proteomics will shift 
from a “discovery” to a “re-mea-
surement” mode, as most proteins 
and peptides are measured and 
deposited in databases (Kuster et 
al., 2005). This will lead to increas-
ingly comprehensive but also faster 
and more accessible whole-pro-
teome quantitation.
There are already compelling 
reasons to consider proteomics 
as a complement or alternative to 
mRNA-based measurements. First, 
in areas in which microarray mea-
surement is not feasible, proteomics 
is becoming a viable alternative to 
determine gene expression on a 
large scale. Blood and other body 
fluids are prime examples because 
proteins of interest are mainly extra-
cellular and mRNA measurements 
are not directly relevant. Second, 
measuring actual protein levels, 
instead of using message levels as 
a proxy, is highly attractive in spite 
of the added experimental complex-
ity. The proteomic measurement 
already delivers the desired end 
point, namely the protein expres-
sion level of a gene of interest. In 
contrast, a change observed on a 
microarray may need to be followed 
up by RT-PCR and western blot-
ting experiments to determine if the 
observed change carries through 
to the protein level. In an ideal (not 
resource constrained) world both 
microarray and proteomic measure-
ments would be performed, which 
would have the further advantage 
of directly differentiating those 
changes that are due to increased 
transcription from those that are 
due to alterations in translation or 
protein stability.
An additional reason why we 
believe proteomics will become the 
“new genomics” is that it is not limited 
to expression profiling of the whole 
cell. Cellular compartments and 
organelles and their time-resolved 
dynamics are readily accessible to 
this technology. First generation 
proteomic maps of the substruc-
tures of the cell already exist and 
they can be “overlaid” onto genomic 
data sets, in effect giving them sub-
cellular resolution. Moreover, the 
classical approaches for studying 
cellular dynamics are all fluores-
cence and microscopy based. As 
shown recently with the nucleolus as 
a model system, these methods can 
be combined with quantitative and 
time-resolved proteomics to bring 
the power of these high-throughput 
methods to cell biology (Andersen et 
al., 2005).
Another area that is accessible to 
proteomics but not to genomics is the 
large-scale measurement of protein 
modifications and their quantitative 
changes upon perturbations to the 
cell. Often these are just as important 
for protein activity as protein expres-
sion levels. SILAC- or iTRAQ-based 
quantitative proteomics is capable of 
determining posttranslational modifi-
cations in complex proteomes, espe-
cially if modified peptides can be 
biochemically enriched. For exam-
ple, site-specific and time-resolved 
changes in phosphorylation upon 
growth factor stimulation in a “phos-
phoproteome” of more than 6000 
sites have been measured (Olsen 
et al., 2006). Thus, proteomics can 
determine the cellular response to 
any perturbation at the level of pro-
tein activation, such as phosphoryla-
tion, and it can determine the down-
stream consequences in terms of 
gene expression changes. Such data 
will give us unprecedented insight 
into how cells make decisions and it 
will likely serve as a cornerstone of 
systems biology.
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